Exosens stock soars nearly 10% and takes the lead in the SBF 120
The publication of new annual targets propels the Bordeaux-based optronic company to the top of the SBF 120 this Thursday morning. The surge occurs as the stock recovers its moving averages after several weeks of pressure, in a broadly stable European market.
Exosens leads the SBF 120 with a gain of nearly 10% driven by its targets revision
Exosens climbs 9.84% to €59.70 during the session, posting the strongest gain in the SBF 120. This surge follows the upward revision of 2026 targets announced this morning: the group now expects revenue growth of approximately 20%, with a ceiling set at €570 million, and adjusted EBITDA growth of around 25%. Publication of the nine-month results is expected on October 27, just over a month away.
The CAC 40 gains 0.22% during the session, while the SBF 120 advances 0.21%, meaning the stock's outperformance is clear. Over the week, Exosens is already up 6.13%, but remains down 10.63% over a month, showing that today's rise partially catches up a recent decline without entirely erasing it.
A recovery above moving averages that strengthens the stock's technical setup
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The session's surge repositions the stock technically above all of its moving averages. The price at €59.70 exceeds the 20-day MA at €57.86 (spread of +3.18%) and now sits near the 50-day MA at €59.43, with a spread of only +0.45%. It also breaks through the 200-day MA at €58.85, with a spread of +1.44%.
This triple recovery is noteworthy: just days ago, the stock had fallen back below all these levels, in a pressured configuration. The RSI at 37 remains in the lower zone, far from any overbought signal, leaving room before a potential technical resistance at €66.80. The next publication of nine-month results on October 27 will be the next information milestone on the group's trajectory.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
